Skip to main content
KL logo

KL — Investor Relations & Filings

Ticker · 6431 ISIN · KYG532651075 TW Manufacturing
Open in API
Filings indexed 30 across all filing types
Latest filing 2026-05-23 Audit Report / Informat…
Country TW Taiwan
Listing TW 6431

About KL

http://www.kl-holdings.com/

Kuangli Bio-Tech Holdings Co., Ltd. is a biotechnology enterprise specializing in the development, manufacturing, and distribution of skincare and health solutions. The company provides comprehensive OEM and ODM services for a broad range of cosmetic products, including essences, facial masks, lotions, and sunscreens. Beyond its core beauty business, the group has expanded into the precision health sector, focusing on cell therapy research, clinical applications, and anti-aging treatments. By integrating high-tech professional expertise and fostering cross-disciplinary industry-academic collaborations, the company delivers precise health management solutions. Kuangli Bio-Tech maintains a strong commitment to innovation through its dedicated R&D teams and specialized laboratories, aiming to advance the practical application of biotechnology in both the aesthetic and medical fields.

Recent filings

Filing Released Lang Actions
114年第4季財務報告書 — 202504_6431_AIA.pdf
Audit Report / Information Classification · 87% confidence The document is a standalone package of consolidated financial statements accompanied by an Independent Auditors’ Report for the years ended December 31, 2025 and 2024. It includes detailed audit opinions, key audit matters, audit responsibilities, and full financial statements with notes and accounting policies. This is not a full annual report with management discussion & analysis or corporate narrative, nor an announcement of a report. It is a standalone audited financial statement filing. Therefore it best fits the “Audit Report / Information” category (AR).
2026-05-23 English
114年第4季財務報告書 — 202504_6431_AI1.pdf
Audit Report / Information Classification · 91% confidence The document is titled as the consolidated financial report (“合併財務報告”) together with the auditor’s report (“會計師查核報告”) for 光麗生技控股股份有限公司及其子公司 covering two fiscal years. It includes the independent auditor’s opinion, consolidated balance sheet, income statement, cash flow statement, equity movement and extensive notes. There is no management discussion & analysis or other narrative sections typical of a full annual report (10-K). This is therefore a standalone audited financial statement filing, which matches our definition for Audit Report / Information (AR).
2026-05-23 Chinese
114年第4季財務報告書 — 202503_6431_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed consolidated financial report for 光麗生技控股股份有限公司及子公司 covering the third quarter of 民國114年 and 民國113年 (i.e., Q3 interim period). It contains a CPA review report under IFRS 34 (“Interim Financial Reporting”), and includes full interim balance sheet, income statement, statement of changes in equity, cash flow statement and extensive notes. This is clearly an actual interim/quarterly financial report, not merely an announcement or summary. Therefore, it should be classified as an Interim / Quarterly Report (IR). 9M 2025
2026-05-23 Chinese
114年第4季財務報告書 — 202502_6431_AI1.pdf
Interim / Quarterly Report Classification · 93% confidence The document is a consolidated financial report and auditor’s report covering the second quarter (interim period) of fiscal years 114 and 113, including full interim balance sheet, income statement, cash flows, equity changes, and detailed notes prepared under IAS 34 “Interim Financial Reporting.” It is clearly an interim/quarterly report rather than a full annual report or a simple announcement. Therefore it should be classified as an Interim/Quarterly Report. Q2 2025
2026-05-23 Chinese
114年第4季財務報告書 — 202501_6431_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report for the first quarter of the fiscal years 民國114 and 113 (Q1 ending March 31), including a full set of interim financial statements (balance sheet, income statement, equity changes, cash flows, detailed notes) and an external accountant’s review report under IFRS 34 “Interim Financial Reporting.” It clearly contains substantive financial data for a period shorter than a full year. This matches the definition of an Interim/Quarterly Report (IR). Q1 2025
2026-05-23 Chinese
115年年報及股東會資料 — 2026_6431_20260612F17.pdf
Major Shareholding Notification Classification · 85% confidence The document is a statutory disclosure listing the top ten shareholders of the company, including share counts, percentages, nominee holdings, and inter-relationship details among them. This matches the Major Shareholding Notification category (MRQ).
2026-05-22 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.